Skip to Content

FUS Ablation Feasible for Intermediate-Risk Prostate Cancer

WEDNESDAY, Feb. 10, 2021 -- Targeted focal therapy with magnetic resonance imaging (MRI)-guided focused ultrasound ablation is feasible for the treatment of intermediate-risk prostate cancer, according to a study published online Feb. 2 in Radiology.

Sangeet Ghai, M.D., from the University of Toronto, and colleagues conducted a prospective phase II trial involving men with unifocal clinically significant prostate cancer visible at MRI who were treated with transrectal MRI-guided focused ultrasound between February 2016 and July 2019. MR thermography was used to perform real-time ablation monitoring. At treatment completion, nonperfused volume was measured.

The researchers found that all 44 men successfully completed treatment, including 36 and eight with grade group 2 and 3 disease, respectively. There were no major treatment-related adverse events reported. At five-month biopsy, 41 of the participants (93 percent) were free of clinically significant prostate cancer at the treatment site. At baseline and at five months, both median International Index of Erectile Function-15 (IIEF-15) and International Prostate Symptom Score measurements were similar. Compared with smaller ablations, larger ones (≥15 cm3) were associated with a reduction in IIEF-15 scores at six weeks.

"By combining the high-intensity focused ultrasound device with MRI, we can target our treatment to the exact location, because we're able to pinpoint precisely where the tumor is," Ghai said in a statement.

Several authors disclosed financial ties to pharmaceutical and medical technology companies, including Insightec Ltd., which partially funded the study.

Abstract/Full Text

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: February 2021

Read this next

Mortality Gap Between Cancer, Heart Disease Narrowing for Women Younger Than 65

THURSDAY, Feb. 25, 2021 -- For women aged younger than 65 years, the mortality gap between cancer and heart disease is narrowing, according to a study published online Feb. 8 in...

Early-Onset T1DM Negatively Impacts Brain Development Over Time

THURSDAY, Feb. 25, 2021 -- Negative changes in brain volumes and cognitive scores persist over time in children with early-onset type 1 diabetes, according to a study published...

Racial/Ethnic Minorities Underrepresented in Vaccine Trials

THURSDAY, Feb. 25, 2021 -- There is underrepresentation of racial/ethnic minorities and older patients among U.S.-based vaccine clinical trials, while female adults are...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.